Crescendo Biologics selects current CFO Theodora Harold as new CEO

pharmafile | April 4, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo 

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack as the company’s new CEO.

Cambridge University graduate Harold will succeed Dr Pack at the beginning of next month, after he steps down from his current position on 1 May 2019.

Kevin Johnson, Non-Executive Chairman of Crescendo Biologics, commented: “On behalf of the Board, I would like to thank Peter for his significant contribution to Crescendo over the years, both as an investor advising the Board and as CEO, where he successfully transitioned the Company from a platform company to a developer of multifunctional therapeutics and also steered the $790 million deal with Takeda. In that time, he has built a strong team around him – with one of the key elements being Theodora – and he has transformed the business. We wish him the best for the future.”

Harold, who has worked closely with Dr Pack since joining Crescendo in October 2016, has played a central role in developing the business in recent years.

While raising $70 million for the development of cancer treatment CB307 in 2018, Harold has played a fundamental in running the finances and operations of the firm for the past few years. More recently she took on the role of CBO, alongside her responsibilities as CFO, in which she was responsible for business development.

Prior to joining Crescendo, Harold held both industry and corporate finance roles in a number of private and listed biotechs including: PsiOxus Therapeutics Ltd, MISSION Therapeutics Ltd, OrthoMimetics Ltd and Cytomyx Holdings plc.

Harold began her career as a chartered accountant at ‘Big Four’ auditor PricewaterhouseCoopers (PWC) after studying classics at Trinity College, Cambridge.

On Harold’s appointment Kevin Johnson said: “Theodora has been a driving force for the Company since she joined. Not only has she made a significant difference to the day-to-day running of the Company, but she has been a major contributor to the corporate, business development and operational strategies.

“The decision to appoint Theodora to succeed Peter was a straightforward and a unanimous one because of her in-depth knowledge of the business and industry as a whole. She has worked tirelessly to build the business so far and she has exciting ambitions for the Company in the longer term.”

Dr Peter Pack added: “I have been extremely fortunate to work at such an extraordinary Company and with the great team at Crescendo. It is now a very different business to the one I joined back in 2015 and I am very proud of what we have achieved together. I believe the time is right to step down but I will keep tight links with the British biotech industry. It is now my pleasure to hand over the stewardship of the Company to Theodora who has been a significant driver of the business since she joined.”

Related Content


CEO of PixarBio Corporation sentenced to prison for defrauding investors

Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …


FibroGen rocked by unexpected death of CEO Thomas B Neff

In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, …


AstraZeneca spends more than twice as much as expected on new HQ

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the …

Latest content